Search
Etranacogene dezaparvovec
go.drugbank.com/drugs/DB16791ApprovedInvestigational[L44156] It delivers a copy of the deficient gene that results in cell transduction and an eventual increase in circulating factor IX activity. … [L44181] Hemophilia B is the second most common type of hemophilia,[L44181] with a prevalence of approximately one in 40,000.
Trandolapril
go.drugbank.com/drugs/DB00519ApprovedInvestigationalIt is metabolized to its biologically active diacid form, trandolaprilat, in the liver. … ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS).
Categories: Agents Acting on the Renin-Angiotensin SystemZalifrelimab
go.drugbank.com/drugs/DB15632InvestigationalZalifrelimab is under investigation in clinical trial NCT03894215 (Phase 2 Study of Anti-pd-1 Independently or in Combination With Anti-ctla-4 in Second-line Cervical Cancer).
Synonyms: A human monoclonal antibody targeting cytotoxic T lymphocyte associated protein 4 (ctla4)Camrelizumab
go.drugbank.com/drugs/DB14776InvestigationalCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
Rilpivirine
go.drugbank.com/drugs/DB08864ApprovedInvestigationalRilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients.[A31328] It is a diarylpyrimidine derivative. … [A31329] The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's
Mixtures: Complera, CompleraCategories: Antivirals used in combination for the treatment of HIV infectionsAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalIt is administered in combination with appropriate antibiotic therapy as the immunoglobulin itself is not known to have direct antibacterial activity against anthrax bacteria, which otherwise may continue … Available as the product Anthrasil (FDA), the result is a solution for slow IV infusion containing polyclonal antibodies that bind the protective antigen (PA) component of Bacillus anthracis lethal and
Nuvaxovid
go.drugbank.com/drugs/DB15810ApprovedInvestigationala productive infection in humans. … Nuvaxovid (NVX-CoV2373) contains a recombinant mutant S protein that is codon-optimized for baculovirus-mediated expression in Sf9 cells derived from _Spodoptera frugiperda_ together with a Matrix-M adjuvant
AVR118
go.drugbank.com/drugs/DB04979InvestigationalAVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment … AVR118 represents a new type of biopolymer chemistry that also possesses novel immunomodulator activity.
Letermovir
go.drugbank.com/drugs/DB12070ApprovedInvestigationalLetermovir recieved approval from the FDA on November 8th, 2017 for use in prophylaxis of cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients. … [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.
Palbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigationalPalbociclib is a piperazine pyridopyrimidine[A176792] that acts in the cell cycle machinery. … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index